Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs

Journal of Managed Care Pharmacy

Volumn 15, Issue 4, 2009, Pages 323-334

  Belperio, Pamela S ^a   Mole, Larry A ^a   Boothroyd, Derek B ^a   Backus, Lisa I ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; TIPRANAVIR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE REGISTRY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG USE; EVALUATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MEDICAL RECORD REVIEW; OUTPATIENT; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; THERAPY RESISTANCE; VETERAN;

EID: 66749149399     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.4.323     Document Type: Article

References (25)

1. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348(22):2175-2185
2. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348(22):2186-2195
3. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Inject Dis. 2006;43(10):1337-1346
4. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis. 2006;43(10):1347-1356
5. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169-1178
6. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36(5):1011-1019
7. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711-718
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed May 2, 2009; Pages 30-32, 38 (Table 6).
9. Holodniy M, Hornberger J, Rapoport D, et al. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatmentnaïve HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr. 2007;44(1):20-29.
10. McNaghten AD, Hanson DL; Dworkin MS, Jones JL; Adult/Adolescent Spectrum of HIV Disease Group.. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32(5):499-505.
11. Baillargeon J, Borucki M, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476-1481
12. National Institutes of Health National Heart Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). Update 2004. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/index.htm. Accessed May 2, 2009.
13. Owen PS, Golightly LK, MacLaren R, Ferretti KA, Badesch DB. Formulary management of recombinant factor VIIa at an academic medical center. Ann Pharmacother. 2008;42(6):771-776
14. Kamps GB, Stewart RE, van Der Werf GT, Schuling J, Jong BM. Adherence to the guidelines of a regional formulary. Fam Pract. 2000;17(3):254-260
15. Whipps D, Zebrowski L, Aseneta A, et al. Fluoroquinolone-use evaluation for acute cystitis. J Manag Care Pharm. 1996;2:564-568 Available at: http://www.amcp.org/data/jmcp/research-I5-564-568.pdf.
16. Burk M, Furmaga E, Dong D, Cunningham F. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the Veterans Affairs Health System. J Manag Care Pharm. 2004;10(5):423-432 Available at: http://www.amcp.org/data/jmcp/Formulary%20Management-423-432.pdf.
17. Barber N. What constitutes good prescribing? BMJ. 1995;310(6984):923-25.
18. Bergman U, Popa C, Tomson Y, et al. Drug utilization 90% - a simple method for assessing the quality of drugs prescribing. Eur J Clin Pharmacol. 1998;54(2):113-118
19. Gora-Harper ML, Hessel E 2nd, Shadick D. Effect of prescribing guidelines on the use of neuromuscular blocking agents. Am J Health Syst Pharm. 1995;52(17):1900-1904
20. Mamdani M, Ching A, Golden B, Melo M, Menzefricke U. Challenges to evidence-based prescribing in clinical practice. Ann Pharmacother. 2008;42(5):704-707
21. Boffito M, Moyle G, Hill A, et al. The pharmacokinetic profile of darunavir with low-dose ritonavir (DRV/r) in various multiple dose regimens over 120 hours. Poster presented at: Ninth International Workshop on Clinical Pharmacology of HIV Therapy; April 7-9, 2008; New Orleans, LA. Abstract P31.
22. DeJesus E, Ortiz R, Khanlou H, et al. Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in antiretroviral treatment-naïve HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211). Poster presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, IL. Abstract H-718b.
23. Clumeck N, van Lunzen J, Chiliade P, et al. ARTEMIS: efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve patients. Poster presented at: European AIDS Conference; October 24-27, 2007; Madrid, Spain. Abstract LBPS7/5.
24. Katlama C, Carvalho M, Cooper D, et al. TMC114/r outperforms investigator-selected Pls in 3-class-experienced patients: week 24 primary efficacy analysis of POWER 1 (TMC114-C213). Poster presented at: 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
25. Wilkin T, Haubrich R, Steinhart CR, et al. POWER 2 (TMC114-C202 study) Week 24 efficacy analysis. Presented at: 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16-19, 2005; Washington, DC.